Emily C. Ayers, MD, discusses recent developments in chronic lymphocytic leukemia.
Emily C. Ayers, MD, a hematologist/oncologist and an assistant professor at University of Virginia Health, discusses recent developments in chronic lymphocytic leukemia (CLL).
One development that has occurred within the past few years is fixed-duration therapy with venetoclax (Venclexta), in which patients receive treatment for 1-2 years depending on their line of therapy, Ayers explains. From there, patients can be monitored off treatment.
Testing for minimal residual disease (MRD) is another exciting advancement, although investigators are still working to fully understand the role of MRD in patients with CLL, Ayers says. While more research is needed, the field may be able to better identify patients who can be taken off treatment due to their deep, durable remissions, Ayers concludes.